Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2024
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
Toxicology Mechanisms and Methods|April 21, 2015
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acidJacqueline M Tarrant, Preeti Dhawan, Jatinder Singh, et al.
Neoplasia (New York, N.Y.)|January 10, 2014
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical modelsJill M Spoerke, Carol O'Brien, Ling Huw, et al.
Plos One|October 7, 2014
Structural basis for resistance to diverse classes of NAMPT inhibitorsWeiru Wang, Kristi Elkins, Angela Oh, et al.
Cell Reports|October 4, 2018
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell FunctionSairy Hernandez, Jing Qing, Rebecca Hong Thibodeau, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 2014
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferaseTanja S Zabka, Jatinder Singh, Preeti Dhawan, et al.
Cell Metabolism|July 26, 2018
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell StateAnneleen Daemen, Bonnie Liu, Kyung Song, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2013
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Kenneth W Bair, Timm Baumeister, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2024
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
Toxicology Mechanisms and Methods|April 21, 2015
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acidJacqueline M Tarrant, Preeti Dhawan, Jatinder Singh, et al.
Neoplasia (New York, N.Y.)|January 10, 2014
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical modelsJill M Spoerke, Carol O'Brien, Ling Huw, et al.
Plos One|October 7, 2014
Structural basis for resistance to diverse classes of NAMPT inhibitorsWeiru Wang, Kristi Elkins, Angela Oh, et al.
Cell Reports|October 4, 2018
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell FunctionSairy Hernandez, Jing Qing, Rebecca Hong Thibodeau, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 16, 2014
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferaseTanja S Zabka, Jatinder Singh, Preeti Dhawan, et al.
Cell Metabolism|July 26, 2018
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell StateAnneleen Daemen, Bonnie Liu, Kyung Song, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2013
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Kenneth W Bair, Timm Baumeister, et al.
Pageof 10